Salvador Blanch

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology · 2022 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

Bárbara Adamo, Meritxell Bellet, Laia Paré et al. · Breast Cancer Research · 2019 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós et al. · Med · 2024 · 39 citations

Medicine, Oncology, Pharmacotherapy +16

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

Antonio Llombart‐Cussac, José Manuel Pérez-García, Manuel Ruíz Borrego et al. · EClinicalMedicine · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

María Gión, Isabel Blancas, Patricia Cortez-Castedo et al. · Nature Medicine · 2025 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +17